Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Report

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-1-68038-518-2
Number of Pages: 120
Format: Electronic (PDF)

Historical Range: 2019 - 2021
Industry: Healthcare

Market Segmentation

NASH Biomarkers Type Outlook (Revenue, USD Million, 2018 - 2030)
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Others
NASH Biomarkers End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
NASH Biomarkers Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America NASH Biomarkers Market, By Type
    - Serum Biomarkers
    - Hepatic Fibrosis Biomarkers
    - Apoptosis Biomarkers
    - Oxidative Stress Biomarkers
    - Others
  - North America NASH Biomarkers Market, By End-use, (USD Million)
    - Pharma & CRO Industry
    - Hospitals
    - Diagnostic Labs
    - Academic Research Institutes
  - U.S.
    - U.S. NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - U.S. NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Canada
    - Canada NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Canada NASH Biomarkers Market, By End-use
- Europe
  - Europe NASH Biomarkers Market, By Type
    - Serum Biomarkers
    - Hepatic Fibrosis Biomarkers
    - Apoptosis Biomarkers
    - Oxidative Stress Biomarkers
    - Others
  - Europe NASH Biomarkers Market, By End-use
    - Pharma & CRO Industry
    - Hospitals
    - Diagnostic Labs
    - Academic Research Institutes
  - U.K.
    - U.K. NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - U.K. NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Germany
    - Germany NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Germany NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - France
    - France NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - France NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Spain
    - Spain NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Spain NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Italy
    - Italy NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Italy NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
- Asia Pacific
  - Asia Pacific NASH Biomarkers Market, By Type
    - Serum Biomarkers
    - Hepatic Fibrosis Biomarkers
    - Apoptosis Biomarkers
    - Oxidative Stress Biomarkers
    - Others
  - Asia Pacific NASH Biomarkers Market, By End-use
    - Pharma & CRO Industry
    - Hospitals
    - Diagnostic Labs
    - Academic Research Institutes
  - Japan
    - Japan NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Japan NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - China
    - China NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - China NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - India
    - India NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - India NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - South Korea
    - South Korea NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - South Korea NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Australia
    - Australia NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Australia NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
- Latin America
- MEA
  - MEA NASH Biomarkers Market, By Type
    - Serum Biomarkers
    - Hepatic Fibrosis Biomarkers
    - Apoptosis Biomarkers
    - Oxidative Stress Biomarkers
    - Others
  - MEA NASH Biomarkers Market, By End-use
    - Pharma & CRO Industry
    - Hospitals
    - Diagnostic Labs
    - Academic Research Institutes
  - South Africa
    - South Africa NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - South Africa NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - Saudi Arabia
    - Saudi Arabia NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - Saudi Arabia NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes
  - UAE
    - UAE NASH Biomarkers Market, By Type
      - Serum Biomarkers
      - Hepatic Fibrosis Biomarkers
      - Apoptosis Biomarkers
      - Oxidative Stress Biomarkers
      - Others
    - UAE NASH Biomarkers Market, By End-use
      - Pharma & CRO Industry
      - Hospitals
      - Diagnostic Labs
      - Academic Research Institutes

Non-alcoholic Steatohepatitis Biomarkers Market Dynamics

Driver: Increasing prevalence of chronic liver disorders

The increasing prevalence of chronic diseases, such as renal diseases, deep vein thrombosis, pulmonary embolism, and cardiovascular disorders, is a major factor driving the global market. According to WHO, in 2021, cardiovascular diseases led to an estimated 17.9 million people deaths, representing 32% of global mortalities. Moreover, according to the CDC, heart disease is the leading cause of death in the U.S., leading to the death of one in 34 patients every 34 seconds. Furthermore, about 697,000 people in the U.S. died from cardiovascular disorders in 2020; among them, coronary artery disease and heart attack were the most common causes. In addition, a heart attack is experienced by around 805,000 people in the U.S. each year and the majority of attacks are first-time attacks. Moreover, an increase in the prevalence of chronic conditions has been observed over the past few years, which includes diabetes and cancer. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases are expected to be diagnosed in the U.S., accounting for 609,360 deaths.

Driver: Growing demand for non-invasive diagnostics in this space

Increasing demand for noninvasive diagnostic tools, coupled with rising patient awareness levels, is expected to boost the development of NASH biomarkers. The high cost of liver biopsy, invasiveness, and limited acceptance by patients are factors responsible for lower adoption of this technology. The liver biopsy process wherein a small piece of liver tissue is extracted via a needle is the gold standard for measuring the efficacy of NASH. However, this method is costly and intrusive. Due to this drawback, noninvasive and affordable diagnostic methods like biomarker tests have been created. To develop biomarker tests, many large firms have invested a considerable sum of money in R&D. However, non-invasive tests are taken into consideration to offer easy-to-use tests. For instance, Enhanced Liver Fibrosis (ELF) is a serum-based noninvasive test that can notably measure liver functions. The aforementioned factors are expected to boost the demand for noninvasive diagnostic tools such as serum biomarkers for NASH diagnosis. The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

Restraint: High rate of underdiagnosis

With increasing prevalence of obesity and type 2 diabetes, conditions that are frequently associated with NASH, there are major limitations associated with the diagnosis and therapeutics for the condition. Moreover, the under-diagnosis of the condition serves as a major challenge for market growth. The disease is currently underdiagnosed due to multiple factors, such as:

Lack of awareness among healthcare providers about the disease condition
Absence of certain obvious symptoms
Lack of awareness among the population
Lack of non-invasive techniques for diagnosis of the disease, designed for the identification of patients with high risk of NASH, and
Lack of EMA and FDA-approved treatment options

There is a significant unmet demand for an accessible, non-invasive technique as an alternative to liver biopsy due to which the diagnosis and treatment of NASH continue to pose serious public health challenge.

What Does This Report Include?

This section will provide insights into the contents included in this non-alcoholic steatohepatitis biomarkers market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Non-alcoholic steatohepatitis biomarkers market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Non-alcoholic steatohepatitis biomarkers market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.